Japanese drug maker Astellas Pharma has entered into a license agreement with Regeneron Pharmaceuticals worth up to $120 million that will allow it to utilize VelocImmune technology as a tool in the discovery of human monoclonal antibody product candidates.
Subscribe to our email newsletter
Astellas will pay $20 million upfront and will make up to five additional annual payments of $20 million. Upon commercialization of any antibody products discovered utilizing VelocImmune, Astellas will pay a mid-single-digit royalty on product sales.
“As described in our recently announced medium term plan, Astellas is building a new technological platform for the development of antibody drugs, and VelocImmune will become an important cornerstone for our R&D capabilities,” said Toshinari Tamura, Astellas’ executive vice president.